Assessment of thyroid cancer risk associated with glucagon‐like peptide 1 receptor agonist use
The totality of data analysed did not suggest an association between liraglutide or semaglutide use and thyroid cancer risk in adults.
Authors
- Tina Vilsbøll (ORCID: https://orcid.org/0000-0002-0456-6787)
- Vanita R. Aroda (ORCID: https://orcid.org/0000-0002-7706-4585)
- Søren Rasmussen
- Sune Dandanell (ORCID: https://orcid.org/0000-0001-6412-2507)
- Jens‐Peter David
- Ceyda T. P. Kristiansen
- Fiona Roberts (ORCID: https://orcid.org/0000-0001-9111-9194)
- Laszlo Hegedüs
- Michael Stellfeld
Institutions
- University of Copenhagen (DK)
- Brigham and Women's Hospital (US)
- Steno Diabetes Centers (DK)
- Harvard University (US)
- University of Southern Denmark (DK)
- Novo Nordisk (Denmark) (DK)
- Odense University Hospital (DK)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1111/dom.70291
- Citations
- 1
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.29